الولايات المتحدة · منصات وبيانات · MarketBeat

Moderna Melanoma Therapy Cuts Recurrence Risk 42% in Phase 3 Trial

نشره MarketBeat · الولايات المتحدة منذ 1 س

Moderna (NASDAQ:MRNA) presented Phase 3 results for intismeran, its individualized neoantigen therapy, in combination with Merck’s pembrolizumab for patients with resected…

اقرأ المقال كاملًا على MarketBeat سجّل الدخول للحفظ

يعرض MarketNews العنوان والملخص كما نشرتهما الوسيلة الإعلامية. المقال الكامل متوفر على موقع الناشر. (www.marketbeat.com)

يستحق القراءة أيضًا

The Motley Fool

Is Berkshire Bending the Rules With Bending Spoons?

Seeking Alpha

Musk says Ukraine violated Starlink terms with offensive drone strikes

MarketWatch

My father-in-law, 81, sold his $75,000 home to pay his daughter’s $50,000 debt. How can I keep him from becoming destitute?

Investing.com

Lula, Bolsonaro rally supporters on final day before Brazil presidential runoff

Yahoo Finance

First Interstate BancSystem: 3 Key Takeaways for Long-Term Investors

TheStreet